Trials / Terminated
TerminatedNCT05074420
A Study of Baricitinib (LY3009104) in Children With COVID-19
A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Given Orally |
Timeline
- Start date
- 2021-12-21
- Primary completion
- 2024-09-05
- Completion
- 2024-11-04
- First posted
- 2021-10-12
- Last updated
- 2025-12-17
Locations
14 sites across 4 countries: United States, Brazil, Mexico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05074420. Inclusion in this directory is not an endorsement.